VitaNova Life Sciences (VNOV) Net Income towards Common Stockholders (2017 - 2026)
VitaNova Life Sciences (VNOV) posted Net Income towards Common Stockholders of -$44362.0 for Q1 2026, down 223.88% on a QoQ basis from $35810.0 in Q4 2025, and down 160.79% year-over-year from $72978.0 in Q1 2025.
VitaNova Life Sciences (VNOV) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
VitaNova Life Sciences' Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$44362.0 for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 160.79% year-over-year to -$44362.0 in Q1 2026, while the trailing twelve-month figure through Jan 2026 was $745479.0 (up 241.44% YoY) and the FY2025 annual result came in at $850746.0, up 503.94% from the prior year.
- Net Income towards Common Stockholders was -$44362.0 for Q1 2026 at VitaNova Life Sciences, down from $35810.0 in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $800332.0 in Q2 2025 and bottomed at -$55211.0 in Q3 2024.
- A 5-year average of $52625.9 and a median of $2134.0 in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders sank 1236.22% — and 2024, when it surged 3929.4%.
- VitaNova Life Sciences' Net Income towards Common Stockholders stood at $2601.0 in 2022, then slumped by 436.6% to -$8755.0 in 2023, then surged by 472.9% to $32647.0 in 2024, then rose by 9.69% to $35810.0 in 2025, then sank by 223.88% to -$44362.0 in 2026.
- Business Quant data shows VNOV's Net Income towards Common Stockholders at -$44362.0 in Q1 2026, $35810.0 in Q4 2025, and -$46301.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Mckesson | 105.15 Bn | 101.18 Bn | 4.04 Bn | 1.86 Bn |
| 2 | Cencora | 60.58 Bn | 58.40 Bn | 3.59 Bn | 1.63 Bn |
| 3 | Cardinal Health | 53.81 Bn | 49.87 Bn | 2.50 Bn | 380.00 Mn |
| 4 | Henry Schein | 9.71 Bn | 9.57 Bn | 1.07 Bn | 112.00 Mn |
| 5 | Akso Health | 3.28 Bn | 3.28 Bn | - | - |
| 6 | 111 | 651.73 Mn | 572.63 Mn | 23.58 Mn | -2.32 Mn |
| 7 | Accendra Health | 248.02 Mn | -88.86 Mn | 278.03 Mn | - |
| 8 | Edap Tms | 230.14 Mn | 215.14 Mn | 8.15 Mn | -9.08 Mn |
| 9 | VitaNova Life Sciences | 11.51 Mn | 11.01 Mn | 316,343.00 | -44,362.00 |
| 10 | Cosmos Health | 9.57 Mn | 7.41 Mn | 1.38 Mn | -2.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -44,362.00 |
| Oct 31, 2025 | 35,810.00 |
| Jul 31, 2025 | -46,301.00 |
| Apr 30, 2025 | 800,332.00 |
| Jan 31, 2025 | 72,978.00 |
| Oct 31, 2024 | 32,647.00 |
| Jul 31, 2024 | -55,211.00 |
| Apr 30, 2024 | 167,919.00 |
| Jan 31, 2024 | 5,948.00 |
| Oct 31, 2023 | -8,755.00 |
| Jul 31, 2023 | -24,247.00 |
| Apr 30, 2023 | -4,385.00 |
| Jan 31, 2023 | -24,577.00 |
| Oct 31, 2022 | 2,601.00 |
| Jul 31, 2022 | 2,134.00 |
| Apr 30, 2022 | -26,807.00 |
| Jan 31, 2022 | 8,917.00 |
| Oct 31, 2021 | 15,009.00 |
| Jul 31, 2021 | 142,563.00 |
| Apr 30, 2021 | -75,830.00 |